Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Corbus Pharmaceuticals Holding - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CRBP
Nasdaq
2834
https://www.corbuspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Corbus Pharmaceuticals Holding
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
- Apr 12th, 2024 10:40 am
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
- Apr 2nd, 2024 12:00 pm
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Mar 12th, 2024 12:00 pm
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
- Mar 6th, 2024 1:00 pm
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
- Feb 28th, 2024 1:00 pm
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 6th, 2024 2:50 pm
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
- Feb 2nd, 2024 9:01 pm
Retail investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are its biggest bettors, and their bets paid off as stock gained 214% last week
- Feb 1st, 2024 10:58 am
Corbus Pharmaceuticals Announces Pricing of Public Offering
- Jan 31st, 2024 2:19 pm
Corbus Pharmaceuticals Announces Proposed Public Offering
- Jan 30th, 2024 11:55 pm
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
- Jan 29th, 2024 11:57 am
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
- Jan 26th, 2024 12:30 pm
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
- Jan 23rd, 2024 1:00 pm
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
- Jan 9th, 2024 1:00 pm
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
- Dec 18th, 2023 1:00 pm
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
- Dec 1st, 2023 2:40 pm
Corbus Pharmaceuticals Reports Q3 2023 Financial Results with a Net Loss of $10.1 Million
- Nov 7th, 2023 2:56 pm
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 7th, 2023 1:00 pm
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
- Nov 2nd, 2023 12:00 pm
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
- Oct 17th, 2023 12:00 pm
Scroll